20240225-国联证券-Claudin18.2药物_开启胃癌靶向治疗新篇章_26页_1mb

Claudin182 Gastric Cancer Therapy: Market Analysis and Development Summary

Key Developments in Claudin182 Targeted Therapy

• Recent advancements include FDA priority review of Zolbetuximab (AstraZeneca) and high response rates in trials. Notable studies show Osemitamab (Creative BioSpace Group) with 66.7% objective response rate (ORR) and 100% disease control rate (DCR), and ASKB589 (Auspex Pharmaceutical) with 75.0% ORR in gastric cancer and gastric-esophageal junction (GEJ) adenocarcinoma patients.

Market Growth and Opportunity

• The global gastric cancer drug market is expected to grow from $22.1 billion in 2024 to $36.4 billion by 2030, with a compound annual growth rate (CAGR) of 87%. Claudin182-targeted therapies address an unmet clinical need, with broad coverage due to high expression (40%-87%) in gastric cancer patients. Uncertainty regarding regulatory approvals was noted.

Product Development Pipeline

• Monoclonal Antibodies (mAbs): Zolbetuximab has secured FDA priority status, while ASKB589 and Osemitamab show strong efficacy in clinical trials, highlighting their potential as first-line treatments.
• Bispecific Antibodies: Drugs like AZD5863 and IBI389 aim to enhance immune response, with trials focusing on off-tumor immune activation to improve outcomes in gastric cancer.
• Antibody-Drug Conjugates (ADCs): Innovations such as IBI343 and CMG901 target specific kill mechanisms, with ADCs offering promise for low-to-moderate expression levels, potentially expanding patient access.
• CAR-T Therapies: Imprint CAR-T with daratumumab shows potential in overcoming resistance, providing a path toward cures, though safety concerns like CRS (cytokine release syndrome) need ongoing monitoring.

Investment Recommendations

• Focus on companies with Claudin182 pipeline:
  • Auspex Pharmaceutical (ASKB589, III phase trials).
  • Creative BioSpace Group (Osemitamab, broad pipeline including double speciality breakthrough technology).
  • Nevak Therapeutics (targeting Orterica, gamma secretase modulator, for various cancers).
  • Kazekai Pharmaceutical (NBL-015, various indications; AB011, early-stage).

Risk Considerations

• Delays in clinical trial results or regulatory decisions could affect drug timelines.
• Increased competition could impact market share and pricing.
• Sales could be hindered by market education and approval challenges.
• Uncertainty in overseas partnerships may delay market expansion or revenue generation.